| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on April 1, 2005
Accepted on June 8, 2005
Center for Molecular Medicine, University of Connecticut Health Center, Farmington, CT, 06030-3101
* To whom correspondence should be addressed. E-mail: molecularmedicine{at}uchc.edu.
Context. Mutations of HRPT2 are frequent in sporadic parathyroid carcinomas and central to their pathogenesis. However, the potential diagnostic utility of HRPT2 mutation status to distinguish between parathyroid carcinoma and adenoma hinges on the frequency of HRPT2 mutations in benign adenomas. Even a low rate of HRPT2 mutation in adenomas would greatly alter diagnostic specificity because adenomas are far more prevalent than carcinomas. The issue remains open because of the limited number of typical adenomas, not subjected to additional selection criteria, examined in previous studies.
Objective/Design/Patients. To determine the frequency of HRPT2 somatic mutations in a substantial series of typical, sporadic parathyroid adenomas, we directly sequenced coding and flanking splice-junctional regions of all HRPT2 exons in solitary adenomas from 60 patients.
Results/Conclusions. No intragenic HRPT2 mutations were detected, strengthening the degree of specificity of HRPT2 mutation as a feature of sporadic parathyroid carcinoma as opposed to sporadic adenomas. Our observations encourage further pursuit of the diagnostic potential of HRPT2 in parathyroid neoplasia, and support the view that HRPT2 inactivation is not an important participant in the pathogenesis of typical parathyroid adenomas.
This article has been cited by other articles:
 |
|
 |
|
  C C Juhlin, A Villablanca, K Sandelin, F Haglund, J Nordenstrom, L Forsberg, R Branstrom, T Obara, A Arnold, C Larsson, et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification Endocr. Relat. Cancer, June 1, 2007; 14(2): 501 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cetani, E. Ambrogini, P. Viacava, E. Pardi, G. Fanelli, A. G. Naccarato, S. Borsari, M. Lemmi, P. Berti, P. Miccoli, et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur. J. Endocrinol., May 1, 2007; 156(5): 547 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Raue and K. Frank-Raue Primary hyperparathyroidism--what the nephrologist should know--an update Nephrol. Dial. Transplant., March 1, 2007; 22(3): 696 - 699. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Marx and W. F. Simonds Imaging to detect early endocrine cancers. J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2861 - 2863. [Full Text] [PDF]
|
|
|
|
|
|
C Juhlin, C Larsson, T Yakoleva, I Leibiger, B Leibiger, A Alimov, G Weber, A Hoog, and A Villablanca Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr. Relat. Cancer, June 1, 2006; 13(2): 509 - 523. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
